Are you Dr. Pardanani?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 73 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
200 1st St SW
Rochester, MN 55905Phone+1 507-284-2511
Summary
- Dr. Animesh Pardanani, MD is an oncologist in Rochester, Minnesota. He is currently licensed to practice medicine in Minnesota, Wisconsin, and South Dakota. He is affiliated with Mayo Clinic Hospital - Rochester and is an Assistant Professor at Mayo Medical School.
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2003
Icahn School of Medicine at Mount Sinai/Morningside/WestResidency, Internal Medicine, 1997 - 2000- Mayo Clinic College of MedicineClass of 1992
Certifications & Licensure
SD State Medical License Active through 2027
MN State Medical License 2000 - 2026
WI State Medical License 2024 - 2025
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) Start of enrollment: 2009 Nov 01
- Clinical Study of PM01183 in Patients With Acute Leukemia or Relapsed/Refractory Myelodysplastic Syndrome Start of enrollment: 2011 May 01
- Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients Start of enrollment: 2011 Jul 01
Publications & Presentations
PubMed
- 1 citationsOutcome of Splenectomy in JAK2 Inhibitor Treated Patients With Myelofibrosis: A Mayo Clinic Experience in 34 Consecutive Cases.Patricia Carey, Animesh Pardanani, Patrick Starlinger, Ayalew Tefferi, Naseema Gangat
American Journal of Hematology. 2025-03-01 - 2 citationsMayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating Agent.Naseema Gangat, Azeem Elbeih, Nour Ghosoun, Kristen McCullough, Fnu Aperna
American Journal of Hematology. 2025-02-01 - TP53 Mutations in Myeloproliferative Neoplasms: Context-Dependent Evaluation of Prognostic Relevance.Ayalew Tefferi, Maymona Abdelmagid, Giuseppe G Loscocco, Saubia Fathima, Kebede H Begna
American Journal of Hematology. 2025-01-28
